Immunovant(US:IMVT) Globenewswire·2025-08-11 11:00Core Insights - Immunovant, Inc. reported corporate updates and financial results for the quarter ended June 30, 2025, focusing on its clinical-stage immunology developments and financial performance [1][4]. Recent Highlights and Upcoming Milestones - In June 2025, Immunovant initiated two potentially registrational trials for IMVT-1402, one for Graves' disease (GD) and another for Sjögren's disease (SjD) [1][10]. - The company is on track with clinical development timelines for IMVT-1402 across six indications, including GD, difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), SjD, and a proof-of-concept trial in cutaneous lupus erythematosus (CLE) [1][10]. - Remission data from the batoclimab proof-of-concept study in GD is expected to be reported at the American Thyroid Association Annual Meeting in September 2025 [2][10]. - Results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and top-line results from the proof-of-concept trial in CLE are anticipated in 2026 [3]. Financial Highlights - As of June 30, 2025, Immunovant's cash and cash equivalents totaled approximately $598.9 million, providing a runway for announced indications through the GD readout expected in 2027 [4][10]. - Research and development (R&D) expenses for the three months ended June 30, 2025, were $101.2 million, an increase from $75.5 million for the same period in 2024, primarily due to clinical trial activities for IMVT-1402 [5][6]. - General and administrative (G&A) expenses rose to $26.0 million for the three months ended June 30, 2025, compared to $18.8 million for the same period in 2024, mainly due to higher personnel-related expenses [6][7]. - The net loss for the three months ended June 30, 2025, was $120.6 million ($0.71 per common share), compared to a net loss of $87.2 million ($0.60 per common share) for the same period in 2024 [8][15].